Trevena, Inc. (TRVN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1232520,
    "name": "Trevena, Inc.",
    "stock_name": "Trevena, Inc.",
    "full_name": "Trevena, Inc.",
    "name_url": "stocks-analysis/trevena-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.01",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "0.01",
    "mcapval": "0.22",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US89532E2081",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "6.76 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/trevena-inc-1232520-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Trevena, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-trevena-inc-technically-bullish-or-bearish-3546882",
        "imagepath": "",
        "date": "2025-09-20 19:42:20",
        "description": "As of 2 September 2025, the technical trend for Trevena, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also indicate a bearish trend. However, the monthly MACD and RSI show mildly bullish and bullish signals, respectively, suggesting some potential for recovery. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -83.33% compared to the S&P 500's 12.22%...."
      },
      {
        "title": "Is Trevena, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-trevena-inc-overvalued-or-undervalued-3543366",
        "imagepath": "",
        "date": "2025-09-20 18:17:32",
        "description": "As of 8 July 2024, Trevena, Inc. has moved from a risky to a does not qualify valuation grade. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.04, an EV to EBIT of -0.66, and an EV to EBITDA of -0.67. Comparatively, peers such as Neurosense Therapeutics Ltd. have a significantly lower EV to EBITDA of -2.5448, indicating that Trevena's valuation metrics are not competitive within the industry.\n\nThe stock has underperformed dramatically, with a year-to-date return of -83.33% compared to the S&P 500's positive return of 12.22%. Over the past year, Trevena's stock has declined by 94.38%, further emphasizing its overvaluation in the current market context...."
      }
    ],
    "total": 7,
    "sid": "1232520",
    "stock_news_url": "https://www.marketsmojo.com/news/trevena-inc-1232520"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Trevena, Inc. technically bullish or bearish?

2025-09-20 19:42:20

As of 2 September 2025, the technical trend for Trevena, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also indicate a bearish trend. However, the monthly MACD and RSI show mildly bullish and bullish signals, respectively, suggesting some potential for recovery. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -83.33% compared to the S&P 500's 12.22%....

Is Trevena, Inc. overvalued or undervalued?

2025-09-20 18:17:32

As of 8 July 2024, Trevena, Inc. has moved from a risky to a does not qualify valuation grade. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -0.04, an EV to EBIT of -0.66, and an EV to EBITDA of -0.67. Comparatively, peers such as Neurosense Therapeutics Ltd. have a significantly lower EV to EBITDA of -2.5448, indicating that Trevena's valuation metrics are not competitive within the industry. The stock has underperformed dramatically, with a year-to-date return of -83.33% compared to the S&P 500's positive return of 12.22%. Over the past year, Trevena's stock has declined by 94.38%, further emphasizing its overvaluation in the current market context....

View All News